Liao Yung-Liang, Chang Sheng-Tsung, Kuo Szu-Yin, Lin Shu-Hui, Chen Chi-Kuan, Chang Kuo-Ming, Chuang Shih-Sung
Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan.
Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):185-9. doi: 10.1097/PAI.0b013e3181c0692b.
Angioimmunoblastic T-cell lymphoma is a nodal peripheral T-cell lymphoma considered to be derived from CD4 follicular helper T cells. It is characterized by the proliferation of arborizing vessels, hyperplastic follicular dendritic cells, and a polymorphous lymphoid infiltrate including large B immunoblasts, which could be polyclonal, oligoclonal, or monoclonal. The polymerase chain reaction-based clonality study of lymphoproliferations is increasingly popular in the diagnostic workup. With the commercially available Biomed-2 protocols, lymphoproliferations with amplicons in the expected size ranges are considered clonal, whereas clonal products outside the expected ranges are extremely rare. We presented the case of a 60-year-old male patient with angioimmunoblastic T-cell lymphoma, in which the neoplastic T cells expressed CD8, bcl-6, and programmed death-1. Furthermore, there was a proliferation of large B cells in this tumor. The results of T-cell receptor gene rearrangement study using the Biomed-2 protocols showed clonal rearrangement with amplicons falling within the expected size ranges. Interestingly, the size of the amplicons detected by the Biomed-2 immunoglobulin heavy chain gene (IgH) rearrangement using FR2/JH primers was around 240 bp, slightly smaller than the expected size ranges. Through cloning, sequencing, and BLAST searches, we confirmed that the FR2/JH amplicon was derived from the IgH rearrangement with a deletion of a short segment. Our case illustrates that polymerase chain reaction amplicons outside the expected size ranges may still be clonal products.
血管免疫母细胞性T细胞淋巴瘤是一种结外型外周T细胞淋巴瘤,被认为起源于CD4滤泡辅助性T细胞。其特征为树枝状血管增生、滤泡树突状细胞增生,以及包括大B免疫母细胞在内的多形性淋巴细胞浸润,这些大B免疫母细胞可能是多克隆、寡克隆或单克隆的。基于聚合酶链反应的淋巴细胞增殖克隆性研究在诊断检查中越来越受欢迎。使用市售的Biomed-2方案,预期大小范围内有扩增子的淋巴细胞增殖被认为是克隆性的,而预期范围外的克隆产物极为罕见。我们报告了一例60岁男性血管免疫母细胞性T细胞淋巴瘤患者,该肿瘤性T细胞表达CD8、bcl-6和程序性死亡-1。此外,该肿瘤中存在大B细胞增殖。使用Biomed-2方案进行的T细胞受体基因重排研究结果显示,扩增子在预期大小范围内的克隆重排。有趣的是,使用FR2/JH引物通过Biomed-2免疫球蛋白重链基因(IgH)重排检测到的扩增子大小约为240 bp,略小于预期大小范围。通过克隆、测序和BLAST搜索,我们证实FR2/JH扩增子源自IgH重排且有一小段缺失。我们的病例表明,预期大小范围外的聚合酶链反应扩增子仍可能是克隆产物。